Meeting
2018 ASCO Annual Meeting
Efficacy of haloperidol versus olanzapine for control of chemotherapy induced nausea and vomiting.
Authors
Soniya Dulal
National Academy of Medical Sciences (NAMS), Bir hospital, Kathmandu, Nepal
Soniya Dulal , Bishnu D. Paudel , Aarati Shah
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Late and Long-Term Effects
Citation
J Clin Oncol 36, 2018 (suppl; abstr 10053)
DOI
10.1200/JCO.2018.36.15_suppl.10053
Abstract #
10053
Poster Bd #
41
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).
First Author: Rudolph M. Navari
Poster
2023 ASCO Annual Meeting
A phase III, double-blind, non-inferiority, randomized controlled trial of antiemetic prophylaxis for highly emetogenic chemotherapy without dexamethasone: CINV POD study.
First Author: Venkatraman Radhakrishnan
Poster
2022 ASCO Annual Meeting
Efficacy of olanzapine, netupitant, and palonosetron in controlling nausea and vomiting associated with highly emetogenic chemotherapy in patients with breast cancer (OLNEPA).
First Author: Camilla Vieira de Reboucas
Poster
2011 ASCO Annual Meeting
Phase III study of single-dose casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting.
First Author: P. J. Hesketh